Disease Management
Collapse Core Gynecologic Oncology Lecture Series

In concert with the Fellowship Program Directors Committee and geared toward young physicians, the Core Gynecologic Oncology Series includes foundational lectures from experts covering all gynecologic cancer disease sites and treatment modalities. This library of lectures will continue to be expanded over time. Please see individual lecture presentations for specific topics and lecturers.

Formats Available: On-Demand
Original Series Date: August 01, 2020
On-Demand Release Date: Available Now
Register &
More InfoRegister & <br />More Info Core Gynecologic Oncology Lecture Series
Collapse Pain Management in Gynecologic Oncology and the Opioid Crisis

SGO presents a webinar on opioid use in gynecologic oncology with speakers from SGO's Education Committee, including Shannon Grabosch, MD, John Geisler, MD, and Allison Puechl, MD.  This timely discussion will outline the scope of the opioid epidemic and what practitioners in gynecologic oncology can do to improve post-surgical prescription and dosing practices. In addition, presenters will provide resources for regulating and monitoring as well as safe disposal practices. 

At the end of this webinar, participants should be able to:
Describe non-narcotic options for post-operative pain management
Use restrictive opioid practices to adequately control post-operative pain. 
Counsel patients regarding expectations for post-operative pain and the benefits of limiting opioid use.
Identify resources for regulatory guidelines within their state.
Counsel patients on proper disposal of opiates. 

Formats Available: On-Demand
Original Series Date: November 01, 2019
On-Demand Release Date: Available Now

Approved Credit:
  • AAPA: 0.50 hours Category 1 CME
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour

  • Register &
    More InfoRegister & <br />More Info Pain Management in Gynecologic Oncology and the Opioid Crisis
    Collapse Paradigm Changes in Front Line Ovarian Cancer - 2020 Annual Meeting Webinar

    Join the Society of Gynecologic Oncology for "Paradigm Changes in Front Line Ovarian Cancer." This session includes seminal data, late-breaking abstracts and more from the SGO 2020 Annual Meeting. Moderators include Thomas Herzog of the University of Cincinnati Cancer Institute and Kathleen Moore, SGO 2020 Annual Meeting Program Co-Chair. 

    JOINT ACCREDITATION
    In support of improving patient care, the Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

    AMA Credit Designation Statement – Physicians
    The Society of Gynecology Oncology designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.

    ANCC Credit Designation Statement – Nurses
    This activity has been approved for a maximum of 1.5 nursing contact hours.

    ACPE Credit Designation Statement – Pharmacists
    Each activity has been approved for a maximum of 1.5 contact hours of pharmacy continuing education credit. UAN number JA0007238-0000-20-015-H01-P

    PAs may claim a maximum of 1.5 AMA PRA Category 1 Credits™ for completing this live activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state or medical society.

     

    Formats Available: Enduring Webinar & CE Credit
    Original Series Date: May 06, 2020

    Approved Credit:
  • AAPA: 1.50 hours Category 1 CME
  • ACCME: 1.50 hours AMA PRA Category 1 Credit(s)
  • ACPE: 1.50 hours CEU
  • ANCC: 1.50 hours Contact Hour

  • Register &
    More InfoRegister & <br />More Info Paradigm Changes in Front Line Ovarian Cancer - 2020 Annual Meeting Webinar
    Collapse PARP Inhibitor Maintenance Therapy after Initial Chemotherapy for Advanced Ovary, Fallopian Tube  and Primary Peritoneal Cancers

    Tune in for a 30-minute discussion of PARP maintenance after initial chemotherapy. 

    This podcast discusses four trials examining the use of PARP inhibitors with initial chemotherapy that have recently been reported. These include:

    • SOLO-1 that examines 2 years of olaparib maintenance in patients with BRCA mutations who responded to initial chemotherapy,
    • PAOLA-1 that examines the addition of olaparib maintenance to bevacizumab maintenance in patients who were treated with chemotherapy and bevacizumab
    • PRIMA that examines niraparib maintenance after completion of initial chemotherapy for high risk patients and
    • VELIA that examines the use of veliparib with initial chemotherapy alone or with initial chemotherapy and as maintenance.

    JOINT ACCREDITATION
    In support of improving patient care, the Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

    AMA Credit Designation Statement – Physicians
    The Society of Gynecology Oncology designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation on each activity.

    ANCC Credit Designation Statement – Nurses
    This activity has been approved for a maximum of 0.5 nursing contact hours.

    ACPE Credit Designation Statement – Pharmacists
    Each activity has been approved for a maximum of 0.5 contact hours of pharmacy continuing education credit. UAN number JA0007238-0000-20-022-H01-P

    PAs may claim a maximum of 0.5 AMA PRA Category 1 Credits™ for completing this live activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state or medical society. 

    Formats Available: On-Demand
    Original Series Date: May 11, 2020

    Approved Credit:
  • AAPA: 0.50 hours Category 1 CME
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour

  • Register &
    More InfoRegister & <br />More Info PARP Inhibitor Maintenance Therapy after Initial Chemotherapy for Advanced Ovary, Fallopian Tube  and Primary Peritoneal Cancers
    Collapse PARP Inhibitors in Gynecologic Oncology: Management and Treatment of Side Effects in Practice

    This slide deck contains useful tips for managing PARP side effects when used to treat gynecologic cancers. This is a printable document that can be downloaded for use in-clinic or viewed on a desktop or mobile device. 

    Formats Available: Slide Deck Download
    Original Series Date: July 22, 2019
    Register &
    More InfoRegister & <br />More Info PARP Inhibitors in Gynecologic Oncology: Management and Treatment of Side Effects in Practice
    Collapse SGO Journal Club: Controversial Topics in Gynecologic Cancer: Heated Intraperitoneal Chemotherapy

    Heated intraperitoneal chemotherapy (HIPEC) at the time of tumor debulking for ovarian cancer has at least one randomized prospective trial demonstrating benefit in overall survival. There is conflicting data as to the approach and timing of HIPEC. Concerns exist regarding toxicity and complexity of use. Significant heterogeneity exists amongst providers whether HIPEC is even discussed as a treatment option with patients. This session will address the pro's and con's of HIPEC to provide clarity on its current role.


    Moderators:
    Susan Zweizig, MD, UMass Memorial Health Care
    Renata Urban, MD, University of Washington

    Discussants:
    Chad Michener, MD, Cleveland Clinic
    Michael McHale, MD, University of California San Diego Health

    Formats Available: SGO Journal Club February 2021
    Original Series Date: February 24, 2021
    Register &
    More InfoRegister & <br />More Info SGO Journal Club: Controversial Topics in Gynecologic Cancer: Heated Intraperitoneal Chemotherapy
    Collapse Targeted Treatment for Ovarian Cancer (Cocktail Part 1)

    Please join us to discuss the indications for PARP inhibitors for ovarian cancer, including maintenance versus treatment. We will explore the role of bevacizumab in ovarian cancer treatment, including platinum sensitive and resistant disease and maintenance. We will delve deeper into novel therapeutics for ovarian cancer, including immunotherapy and antibody drug conjugates.

    JOINT ACCREDITATION

    In support of improving patient care, Society of Gynecologic Oncology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    AMA Credit designation Statement – Physicians This activity is approved for 1.5  AMA PRA Category 1 Credits ™

    ANCC Credit Designation Statement- Nurse This activity is approved for 1.5 ANCC contact hours.

    This activity has not been submitted to ACPE for Pharmacist credit.

    PA's may claim maximum of 1.5 AMA PRA Category 1™ credits for completing this activity.

    Formats Available: On-Demand
    Original Series Date: February 15, 2018
    On-Demand Release Date: Available Now
    Register &
    More InfoRegister & <br />More Info Targeted Treatment for Ovarian Cancer (Cocktail Part 1)
    Collapse Understanding and Applying Molecular Profiling Tests in Ovarian Cancer (Cocktail Part 3)

    This third installment of the COCKTAIL series will help learners understand and interpret clinical genomic testing and will discuss cases to reveal practical clinical applications of next generation sequencing in ovarian cancer.  In addition, learners will understand some of the novel applications of tumor sequencing currently in development.

    DISCLOSURES

    Dr. Jocelyn Chapman, MD -- No Disclosures at this time.
    Dr. David Quigly, PhD -- No Disclosures at this time.

    Formats Available: On-Demand
    Original Series Date: April 24, 2018
    Register &
    More InfoRegister & <br />More Info Understanding and Applying Molecular Profiling Tests in Ovarian Cancer (Cocktail Part 3)